[Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].

Abstract

A multi-center series of 117 patients with malignant lymphoma were analyzed to evaluate the clinical significance of soluble interleukin-2 receptor alpha chain (sIL-2R alpha). The initial levels of sIL-2R alpha ranged from 277 U/ml to 22,800 U/ml with a mean level of 3,451 +/- 4,268 U/ml and a median level of 1,600 U/ml. The sIL-2R alpha levels of the diffuse lymphoma/intermediate-grade subtypes defined by the LSG classification/Working Formulation were higher than those of the follicular lymphoma/low-grade subtypes. There was a tendency for B-cell lymphomas to show higher sIL-2R alpha levels than T-cell lymphomas. The sIL-2R alpha level was correlated with the Ann Arbor clinical stage (I, II versus III, IV), presence or absence of B symptoms, and performance status (0, 1 versus 2, 3, 4) of the patients. The sIL-2R alpha levels were in good accordance with the four risk groups defined by the International Prognostic Indices. Of 21 patients whose tumor burden was serially measured, the coefficients of correlation between sIL-2R alpha and tumor mass were > 0.6 in 18 cases. Sixty-two patients achieved complete remission (CR) during the study; the initial and minimum sIL-2R alpha levels were lower than those of the non-CR patients. This study confirmed that sIL-2R alpha is a convenient and useful marker in the management of malignant lymphoma.

• Authors: Hitoshi Ohno, Takayuki Ishikawa, Hiroyuki Kitajima, Shosaku Nomura, Takayo Suzuki, Hiroshi Konishi, Yoichiro Ohno, Rie Onishi, Yoshiteru Konaka, Nobuyoshi Arima, Shoichi Doi, Kaori Nasu, Takayuki Takahashi, Mitsuru Tsudo, Shirou Fukuhara, Takashi Uchiyama
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 43 Issue 3 Pg. 170-5 (Mar 2002) ISSN: 0485-1439 [Print] Japan
• PMID: 11979748 (Publication Type: English Abstract, Journal Article, Multicenter Study)

Chemical References

• Receptors, Interleukin-2

Topics

• Female
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Prognosis
• Receptors, Interleukin-2 (blood, therapeutic use)
• Risk Factors